Clik here to view.
Cynapsus confirms Parkinson’s treatment in drug trial
Cynapsus Therapeutics (TSX-V:CTH) has released positive top-line data from a human volunteer proof-of-concept trial for APL-130277, a sublingual thin film strip formulation of apomorphine, for the...
View ArticleClik here to view.
Noble starts Cynapsus at buy
Noble Financial Capital Markets has initiated coverage of Cynapsus Therapeutics (TSX-V:CTH) with a “buy” rating and 12-month price target of $1.75. The stock closed at 38 cents on Monday. Cynapsus is...
View ArticleClik here to view.
Cynapsus to start Phase 2 trial of APL-130277
Following communication from the FDA, Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) announced that it will begin Phase 2 clinical studies for APL-130277 immediately. The CTH-105 study will be...
View ArticleClik here to view.
Cynapsus’ drug shown to improve Parkinson’s symptoms
Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has presented data from clinical trials of APL-130277, a sublingual apomorphine thin film under development for the on-demand treatment of off episodes...
View ArticleClik here to view.
BofA, Nomura start Cynapsus at buy
BofA Merrill Lynch and Nomura Securities initiated coverage of Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) with “buy” ratings as BofA set a target price of $33 on the stock and Nomura at $29....
View ArticleClik here to view.
Cynapsus enrolls first patient in Phase 3 trial
Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has enrolled the first patient in the CTH-301 clinical trial, a pivotal Phase 3 study to examine the safety and tolerability of APL-130277 for the acute...
View Article
